 | |
| Clinical data | |
|---|---|
| Trade names | Glurenorm |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | Oral (tablets) |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | High (Tmax = 2–3 hours) |
| Metabolism | Extensivehepatic |
| Onset of action | 1–1.5 hours |
| Excretion | Biliary (95%),renal (5%) |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.046.770 |
| Chemical and physical data | |
| Formula | C27H33N3O6S |
| Molar mass | 527.64 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Gliquidone (INN, sold under the trade nameGlurenorm) is ananti-diabetic medication in thesulfonylurea class.[1] It is classified as a second-generation sulfonylurea. It is used in the treatment ofdiabetes mellitus type 2. It is marketed by the pharmaceutical companyBoehringer Ingelheim (Germany).
Gliquidone is fully metabolized by the liver. Its metabolites are excreted virtually completely with bile (even with long-term administration), thus allowing the use of medication in diabetic patients with kidney disease anddiabetic nephropathy.[2]
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |
